OBJECTIVE: Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia. It has been suggested that refractory schizophrenic patients who fail to respond to neither clozapine nor risperidone may respond to a combination/augmentation strategy of both medicaments. METHOD: Three cases of individuals with unremittent schizophrenia treated via this combination are presented. Response was evaluated by clinical follow-up and PANSS rating scale. RESULTS: Good clinical results with no noticeable adverse side effects, ascertained by a reduction from baseline scores of the Positive and Negative Syndrome Scale (PANSS) were obtained in all three patients. CONCLUSION: The findings from this pilot study suggest this combination as a possible therapeutic approach for treating resistant schizophrenic patients.
OBJECTIVE:Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia. It has been suggested that refractory schizophrenicpatients who fail to respond to neither clozapine nor risperidone may respond to a combination/augmentation strategy of both medicaments. METHOD: Three cases of individuals with unremittent schizophrenia treated via this combination are presented. Response was evaluated by clinical follow-up and PANSS rating scale. RESULTS: Good clinical results with no noticeable adverse side effects, ascertained by a reduction from baseline scores of the Positive and Negative Syndrome Scale (PANSS) were obtained in all three patients. CONCLUSION: The findings from this pilot study suggest this combination as a possible therapeutic approach for treating resistant schizophrenicpatients.
Authors: Vassilis P Kontaxakis; Panayotis P Ferentinos; Beata J Havaki-Kontaxaki; Konstantinos G Paplos; Dimitra A Pappa; George N Christodoulou Journal: Eur Arch Psychiatry Clin Neurosci Date: 2006-08-08 Impact factor: 5.270